Showing 3661-3670 of 5773 results for "".
- SpyGlass Pharma Presents 3-Month Data from the First-In-Human Trial of Its Drug Delivery Platform for Chronic Eye Conditionshttps://modernod.com/news/spyglass-pharma-presents-3-month-data-from-the-first-in-human-trial-of-its-drug-delivery-platform-for-chronic-eye-conditions/2481140/SpyGlass Pharma announced 3-month data from a first-in-human glaucoma treatment trial showing that its breakthrough drug delivery platform lowered IOP in patients with open-angle glaucoma or ocular hypertension. The data were showcased during an oral presentation at the Eyecelerator inn
- ImprimisRx Launches Fortisite (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulationhttps://modernod.com/news/imprimisrx-launches-fortisite-tobramycin-15-vancomycin-5-compounded-antibiotic-formulation/2481135/ImprimisRx announced the availability of Fortisite, which includes a patent-pending compounded combination of Tobramycin 1.5% and Vancomycin 5%. Compounded topical antibiotic formulations may be appropriate to prescribe for patients with clinical needs that are unmet by FDA-
- Alcon Introduces Clareon Toric IOL Featuring Stableforce Haptics Technologyhttps://modernod.com/news/alcon-completes-availability-of-clareon-portfolio-with-clareon-toric-during-aao-2022/2481134/Alcon announced new product launches in the US as well as
- Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitishttps://modernod.com/news/tarsus-launches-look-at-the-lids-campaign-to-encourage-eye-care-professionals-to-identify-and-diagnose-demodex-blepharitis/2481133/Tarsus Pharmaceuticals announced the launch of the “Look at the Lids” disease education campaign for Demodex blepharitis, a common lid margin disease that can negatively impact patients’ daily activities and eyelid health. The novel campaign is designed to encourage ey
- Ocuphire Expands Medical Advisory Board with Seven New KOLs; Expands Leadership Teamhttps://modernod.com/news/ocuphire-expands-medical-advisory-board-with-seven-new-kols-expands-leadership-team/2481132/Ocuphire Pharma announced that it has appointed seven new key opinion leaders (KOLs) across retina, cornea/refractive, and medical optometry to its Medical Advisory Board (MAB). In addition, Ronil Patel, MS, has been promoted to Vice President, Business Development and Market St
- Iridex to Showcase its Non-Incisional Treatments for Glaucoma and Introduce Sweep Management Software at AAO 2022https://modernod.com/news/iridex-to-showcase-its-non-incisional-treatments-for-glaucoma-and-introduce-sweep-management-software-at-aao-2022/2481130/Iridex will showcase non-incisional glaucoma treatments, introduce its Sweep Management Software, and host 8 physician presentations at the 2022 American Academy of Ophthalmology (AAO) annual meeting in Chicago, September 30 – October 3. MicroPulse Transscleral Laser Thera
- Johnson & Johnson Vision Introduces Tecnis Symfony OptiBlue EDOF IOL, the Latest PC-IOL Powered by InteliLight Technologyhttps://modernod.com/news/johnson-johnson-vision-introduces-tecnis-symfony-optiblue-edof-iol-the-latest-pc-iol-powered-by-intelilight-technology/2481128/Johnson & Johnson Vision announced availability of a new presbyopia-correcting IOL (PC-IOL) powered by InteliLight technology, Tecnis Symfony OptiBlue IOL. This extended depth-of-focus (EDOF) lens expands presbyopia correction to more patients and joins Tecnis Synergy IOL, a hi
- Johnson & Johnson Vision Expands Access to Myopia Management for More Patients With Abiliti Overnight Lenseshttps://modernod.com/news/johnson-johnson-vision-expands-access-to-myopia-management-for-more-patients-with-abiliti-overnight-lenses/2481127/Johnson & Johnson Vision announced FDA approval of an expanded range of ACUVUE Abiliti Overnight Therapeutic Lenses for Myopia Management, now up to 6.00 diopters (previously 4.00 diopters). Johnson & Johnson Vision also announced greater availability of the lenses nationwi
- Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the Omni Surgical System as a Standalone Glaucoma Treatment at AAOhttps://modernod.com/news/sight-sciences-to-feature-interactive-panel-discussions-of-real-world-use-of-the-omni-surgical-system-as-a-standalone-glaucoma-treatment-at-aao/2481125/Sight Sciences announced that 12 ophthalmic physicians will present their first-hand experience using the Omni Surgical System as a standalone minimally invasive glaucoma surgery (MIGS) during this year’s annual AAO convention at McCormick Place in Chicago. Meeting delegates are invite
- Visus Therapeutics Acquires Assets of ViewPoint Therapeuticshttps://modernod.com/news/visus-therapeutics-acquires-assets-of-viewpoint-therapeutics/2481124/Visus Therapeutics announced it has expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics. Financial terms of the deal were not disclosed. Founded in 2014, ViewPoint discovered and developed alpha-crystallin aggregation